| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.19 | 0.001 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.002 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.005 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |